Skip to content
Menu

Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.

Read at benzinga.com